New antiretroviral agents for the treatment of HIV infection

Current Infectious Disease Reports

Volumn 6, Issue 4, 2004, Pages 333-339

  Marks, Kristen ^b   Gulick, Roy M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMD 11070; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CAPRAVIRINE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DARUNAVIR; EFAVIRENZ; ELVUCITABINE; ETRAVIRINE; LAMIVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SPD 754; TIPRANAVIR; TNX 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; LIVER DYSFUNCTION; NONHUMAN; REVIEW; VIRUS RESISTANCE; VOMITING;

EID: 4444346813     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-004-0056-8     Document Type: Review

References (46)

1. Geleziunas R, Gallagher K, Zhang H, et al.: HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′, 3′-dideoxy-2′, 3′ -didehydro-5-fluorocytidine (Reverset). Antivir Chem Chemother 2003, 14:49-59.
2. Murphy RL, Schürmann D, Kravec I, et al.: Pharmacokinetics, safety and antiviral activity of the nucleoside Reverset following single doses in HIV-1 infected patients [abstract]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13-16, 2003.
3. Murphy RL, Schürmann D, Beard A, et al.: Tolerance and potent anti-HIV-1 activity of Reverset following 10 days of mono-therapy in treatment-naïve individuals [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
4. Locas C, Ching S, Damment S: Safety profile of SPD754 in Cynomolgus monkeys treated for 52 weeks [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
5. Francis RJ, Lanclos L, Shiveley L, Sawyer J: Pharmacokinetics of SPD754, a new cytidine analogue in healthy volunteers [abstract]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13-16, 2003.
6. Cahn P, Lange J, Cassetti I, et al.: Anti-HIV-1 activity of SPD754, a new NRTI: results of a 10 day monotherapy study in treatment-naive HIV patients [abstract]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13-16, 2003.
7. Collins P, Shiveley L, Anderson C, Bethell R: Analysis of the genotypes of viruses isolated from patients after 10 days monotherapy with SPD754 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
8. Bethell R, Adams J, De Muys J, et al.: Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
9. Fujiwara T, Sato A, El-Farrash M, et al.: S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998, 42:1340-1345.
10. Hayashi S, Amantea M, Hawley P, et al.: Effects of fasting (F), high fat (H) and low fat (L) meals on the pharmacokinetics (PK) of a single oral dose of capravirine (CPV), a nonnucleoside reverse transcriptase inhibitor (NNRTI), in healthy volunteers [abstract]. Paper presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; September 17-20, 2000.
11. Jacobs M, Leoung G, Dezube B, et al.: Pharmacokinetic (PK) interaction of AG1549, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI), with protease inhibitors (PI) [abstract]. Paper presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; January 30-February 2, 2000.
12. Amantea MA, Raber S, Reynolds R, et al.: Pharmacokinetic drug-drug interaction between capravirine, lopinavir/ ritonavir and tenofovir in healthy volunteers [abstract]. Paper presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14-17, 2003.
13. Dezube BJ, Jacobs MS, Leoung G, et al.: A second-generation non-nucleoside reverse transcriptase inhibitor (S-1153) for the treatment of HIV-1 infection: a phase I study [abstract]. Paper presented at the 12th World AIDS Conference. Geneva, Switzerland; June 28-July 3, 1998.
14. Hernandez J, Amdador L, Amantea M, et al.: Short-course monotherapy with AG1549, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) in antiretroviral-naïve patients [abstract]. Paper presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; January 30-February 2, 2000.
15. Wolfe P, Hawley P, Boccia G, et al.: Safety and efficacy of capravirine versus placebo in HIV-infected patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen: results of a phase II, double-blind, placebo- controlled study [abstract]. Paper presented at the 8th Annual Conference on Retroviruses and Opportunistic Infections. Chicago, IL; February 4-8, 2000.
16. Hammond JL, Amantea M, Raber S, et al.: Long-term virological response to capravirine in HIV-infected NNRTI- experienced patients [abstract]. Paper presented in the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14-17, 2003.
17. Ludovici DW, De Corte BL, Kukla MJ, et al.: Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett 2001, 11:2235-2239.
18. Gruzdev B, Rakhmanova A, Doubovskaya E, et al.: A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003, 17:2487-2494.
19. Gazzard BG, Pozniak AL, Rosenbaum W, et al.: An open-label assessment of TMC125, a new next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003, 17:F49-F54.
20. Larder BA, Hertogs K, Bloor S, et al.: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000, 14:1943-1948.
21. Cooper D, Hall D, Jayaweera D, et al.: Baseline phenotypic susceptibility to tipranavir/ritonavir (TPV/r) is retained in isolates from patients with multiple-protease inhibitor (PI-experience) (BI 1182-52) [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 24-28, 2003.
22. McCallister S, Sabo J, Galitz L, Mayers D: An open-label steady state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal healthy volunteers (BI 1182.5) [abstract]. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; February 24-28,2002.
23. Wang Y, Daenzer C, Wood R, et al.: The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in a phase II study in antiretroviral-naive HIV-1-infected patients [abstract]. Paper presented at the 7th Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; January 30-February 2, 2000.
24. Slater L, Farthing C, Jayaweera J, et al.: Safety and efficacy of tipranavir, a novel non-peptidic protease inhibitor (PI), plus ritonavir in PI-failure patients [abstract]. Paper presented at the 41st Interscience Conference on Antimicrobial and Antiviral Chemotherapy. Chicago, IL; December 16-19, 2001.
25. Curry R, Markowitz M, Slater L, et al.: Safety and efficacy of tipranavir, a non-peptidic protease inhibitor, in multiple failure patients (BI 1182.2) [abstract]. Paper presented at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina; July 8-11, 2001.
26. Gathe J, Kohlbrenner VM, Pierone G, et al.: Tipranavir/ ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52 [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 24-28, 2003.
27. Squires K, McCallister S, Lazzarin A, et al.: Tipranavir/ritonavir demonstrates a robust resistance profile in multiple protease inhibitor-experienced patients: correlation of baseline genotype nd antiviral activity in BI 1182.52 [abstract]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13-16, 2003.
28. De Meyer S, Van Marck H, Van Den Bulcke T, et al.: Phenotypic and genotypic profiling of TMC114, a potent next-generation PI, against some 1600 recent PI-resistant clinical isolates [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infection. San Francisco, CA; February 8-11, 2004.
29. Van der Geest R, Van der Sandt, Gille D, et al.: Safety, tolerability and pharmacokinetics of escalating single oral doses of TMC114, a novel protease inhibitor (PI) highly active against HIV-1 variants resistant to other PIs [abstract]. Paper presented at the 41st Interscience Conference on Antimicrobial and Antiviral Chemotherapy. Chicago, IL; December 16-19, 2001.
30. Arasteh K, Clumecket N, Pozniak A, et al.: Antiretroviral activity, safety and pharmacokinetics of TMC114, a next- generation HIV-1 protease inhibitor in multiple PI-experienced patients [abstract]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13-16, 2003.
31. Peeters M, Van Baelen B, De Meyer S, et al.: TMC114/RTV activity in multiple PI-experienced patients: correlation of baseline genotype, phenotype, pharmacokinetics, and IQ with antiviral activity at day 14 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco; CA; February 8-11, 2004.
32. Moore JP, Sattentau GQ, Klasse PJ, Burkly LC: A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformation changes to the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992, 66:4784-4793.
33. Reimann KA, Khunkhun R, Lin W, et al.: A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkey chronically infected with simian immunodeficiency virus. AIDS Res Hum Retroviruses 2002, 18:747-755.
34. Reimann K, Liin W, Bixler S, et al.: A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997, 13:933-943.
35. Boon L, Holland B, Gordon W, et al.: Development of anti- CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology 2002, 172:191-203.
36. Kuritzkes DR, Jacobson J, Powderly WG, et al.: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004, 189:286-291.
37. Jacobson JM, Kuritzkes DR, Godofsky E, et al.: Phase Ib study of the anti-CD4 monoclonal antibody TNX-355 in HIV-1- infected subjects: safety and antiretroviral activity of multiple doses [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
38. Baroudy B: Co-receptor inhibitors [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain; July 7-12, 2002.
39. Schurmann D, Rouzier R, Nougarede R, et al.: SCH D: antiviral activity of a CCR5 receptor antagonist [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
40. Macartney MJ, Dorr PK, Smith-Burchnell C, et al.: In vitro anti- viral profile of UK-427,857: a novel CCR5 antagonist [abstract]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14-17, 2003.
41. Russell D, Bakhtyari A, Jazrawi RP, et al.: Multiple dose study to investigate the safety of UK-427, 857 (100 mg or 300 mg) BID for 28 days in healthy males and females [abstract]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14-17, 2003.
42. Pozniak AL, Fatkenheuer G, Johnson M, et al.: Effect of short- term monotherapy with UK-427,857 on viral load in HIV- infected patients [abstract]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14-17, 2003.
43. Westby M, Whitcomb J, Huang W, et al.: Reversible predominance of CXCR4 utilizing variants in a non-responsive dual tropic patient receiving the CCR5 antagonist UK-427,857 [abstract]. Paper presented at be 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
44. Schols D, Claes S, De Clercq E, et al.: AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans [abstract]. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; February 24-28, 2002.
45. Hendrix C, Collier AC, Lederman M, et al.: AMD-3100 CXCR4 receptor blocker fails to reduce HIV viral load by > 1 log following 10-day continuous infusion [abstract]. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; February 24-28, 2002.
46. Schols D, Vermeire K, Hatse S, et al.: In vitro anti-HIV activity profile of AMD 887, a novel CCR5 antagonist, in combination with the CXCR4 inhibitor AMD 070 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.